Assoc/Prof Peter Henry
Head of Unit/ Associate Professor
Medicine and Pharmacology, School of, Pharmacology, Pharmacy and Anaesthesiology Unit
- Contact details
- School of Medicine and Pharmacology - Pharmacology, Pharmacy and Anaesthesiology Unit
The University of Western Australia (M510)
35 Stirling Highway
CRAWLEY WA 6009
- +61 8 9346 3123
- +61 8 9346 3469
- Personal homepage
- BSc PhD W.Aust.
- Peter is a graduate of UWA, completing a double major in Biochemistry and Pharmacology (Honours), and a PhD in Pharmacology under the supervision of Professor James Paterson. Peter then enjoyed a rewarding 3-year post-doctoral period at the University of Melbourne working with Professor John Horowitz (Department of Clinical Pharmacology, Austin Hospital) before returning to UWA to join the Respiratory Pharmacology group headed by Professor Roy Goldie. In 1991 he was awarded an NHMRC RD Wright Fellowship for New Investigators, and in 1998 appointed to the NHMRC Fellowships Scheme as a Research Fellow. Peter was appointed as a Lecturer in Pharmacology in 2001, and is presently an Associate Professor, and Head of the Pharmacology and Anaesthesiology Unit at UWA.
Peter has spent 20 years investigating novel pathways that protect the lungs from the injurious effects of airborne allergens, respiratory tract viruses, bacterial products and environmental toxins. These studies have typically involved collaborations with scientists from international pharmaceutical companies and academic institutions, and have been extensively funded by the NHMRC. Recently, Peter’s research team has been particularly interested in understanding the role of protease-activated receptors and their signaling pathways in the airways during both health and disease. Peter's group has studied these pathways using a raft of pharmacological approaches ranging from studies of molecules (receptor binding, immunohistochemistry), cells (intracellular signal transduction studies, Ca2+ mobilization, IP3), isolated tissues (smooth muscle contraction, neurotransmitter release) and whole animals (lung function, bronchoalveolar lavage, leukocyte trafficking). His research group currently consists of Ms Tracy Mann (Research Associate), Mr Terence Peters (PhD student) and Ms Leah Bennington (Honours student). Peter has received several Excellence in Postgraduate Teaching nominations (UWA), and two of his PhD students have been awarded passes with distinction.
His current academic responsibilities include being Unit coordinator for Systems Pharmacology PHAR3301 and the Head of the Pharmacology and Anaesthesiology Unit. He has previously held the position of Head of Teaching and Learning Committee for the discipline of Pharmacology.
- 80 peer reviewed papers including:
Saleh SM, Mann TS, Peters T, Betts RJ, Henry, PJ (2008) Influence of dexamethasone on Protease-Activated Receptor-2-mediated responses in the airways. J Pharmacol Exp Ther 324: 622–630.
Judge RK, Henry PJ, Mirtschin P, Jelinek G, Wilce JA (2006) Toxins not neutralized by brown snake antivenom. Toxicol Appl Pharmacol. 213:117-25.
Henry PJ (2005) The protease-activated receptor2 (PAR2) – prostaglandin E2 – EP receptor axis: a potential bronchoprotective unit in the respiratory tract? Eur J Pharm 533:156-170.
Henry, P.J., D’Aprile, A.C., Self, G.J., Hong, T., Mann, T.S. (2005). Inhibitors of prostaglandin transport and metabolism augment PAR2-mediated increases in PGE2 levels and smooth muscle relaxation in mouse isolated trachea. J. Pharmacol. Exp. Ther. 314, 995-1001.
Forbes, E., Smart, V., D’Aprile, A., Henry, P.J., Yang, M., Matthaei, K.I., Rothenberg, M.E., Foster, P.S. & Hogan, S.P. (2004). T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. Gastroenterology 127, 105-118.
Lan, R.S., Stewart, G.A., Goldie, R.G. & Henry, P.J. (2004). Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. Am. J. Physiol. 286, L388-L398.
Henry, P.J., Mann, T.S., D’Aprile, A.C., Self, G.J. & Goldie, R.G. (2002). An endothelin receptor antagonist, SB217242 inhibits airway hyperresponsiveness in allergic mice. Am. J. Physiol., 283, 1072-1078.
Lan, R.S., Stewart, G.A. & Henry, P.J. (2002). Role of Protease-Activated Receptors (PARs) in airway function: a target for therapeutic intervention? Pharmacol. Ther. (in Press).
Yang, M., Hogan, S.P., Henry, P.J., Matthaei, K., McKenzie, A.N.J., Young, I.G., Rothenberg, M.E. & Foster, P.S. (2001). Requirement for IL-4R alpha and STAT-6, and not IL-5, eotaxin and eosinophils in early and late-phase IL-13-mediated AHR Am. J. Resp Cell Mol. Biol., 25, 522-530.
Lan, R.S., Knight, D.A., Stewart, G.A. & Henry, P.J. (2001). Role of PGE2 in protease activated receptor-1, -2, and 4 mediated relaxation in the mouse trachea. Br. J. Pharmacol., 132, 93-100.
Henry, P.J., Carr, M.J., Goldie, R.G. & Jeng, A.Y. (1999). Influence of an ECE inhibitor CGS 26303 on influenza A virus-induced
changes in endothelin content and ET¬B receptor density in mouse airways. Eur. Respir. J., 14, 92-97.
Cocks, T.M., Fong, B., Chow, J.M., Anderson, G.P., Goldie, R.G., Henry, P.J., Carr, M.J., Fraumann, A., Hamilton, J.R. & Moffatt, J.D. (1999). A protective role for protease-activated receptors in the airways. Nature, 398, 156-160.
- Roles, responsibilities and expertise
- Head, Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology
Head, Respiratory Pharmacology Research group
- Funding received
- Chief Investigator on NHMRC and NHF project grants (1991-current)
- ASCEPT (Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists)
ATS (American Thoracic Society)
- Honours and awards
- RD Wright Fellowship (NHMRC)
Research Fellowship (NHMRC)
- Previous positions
- Senior Lecturer in Pharmacology (UWA)
Lecturer in Pharmacology (UWA)
Research Fellow (NHMRC, UWA)
- Unit coordinator of Systems Pharmacology PHAR3301 unit. Teach a wide variety of Pharmacology subjects to graduate and postgraduate Medicine, Dentistry, Science, Pharmacy and Podiatry students.